Hi Scott
I may be completely wrong but I worked on a lithium and sodium inhibited enzyme during my PhD. At the time, it was considered that your chances of actually seeing density for a Li+ ion were slim to nil. Only 2 electrons makes them as tough as hydrogens. My efforts went into trying to prove I had a sodium ion bound over magnesium which is the catalytically active ion Do you have ultra-high resolution? Something I did not.... Are there many examples in the pdb of proteins with Li+ refined? Sorry no real help to you, but curious since it brings up old memories... Joe P Dr Joe Patel _____________________________________________________________________ AstraZeneca Discovery Sciences, Structure & Biophysics UK 50S38, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG Tel +44 (0)1625 233543 Fax +44 (0)1625 230164 joe.pa...@astrazeneca.com <mailto:name.surn...@astrazeneca.com> P Please consider the environment before printing this e-mail From: CCP4 bulletin board [mailto:CCP4BB@JISCMAIL.AC.UK] On Behalf Of Scott Pegan Sent: 12 January 2012 06:10 To: CCP4BB@JISCMAIL.AC.UK Subject: [ccp4bb] Lithium versus Sodium Hey all, Does anyone know of a good article that deals with differentiating between a lithium ion and sodium ion for density in a X-ray structures? Scott -- Scott D. Pegan, Ph.D. Assistant Professor Chemistry & Biochemistry University of Denver Office: 303 871 2533 Fax: 303 871 2254 -------------------------------------------------------------------------- AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 2 Kingdom Street, London, W2 6BD. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking Compliance with our Code of Conduct and Policies.
